Quanfeng Zhao
Pan Ma
Peishu Fu1
Lin Chen
Yang Yang
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1Department of Pharmacy, The First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China
- 2Department of Pharmacy, Women and Children’s Hospital of Chongqing Medical University, Chongqing, China
- 3Department of Pharmacy, Chongqing Health Center for Women and Children, Chongqing, China
by Zhao, Q., Ma, P., Fu, P., Wang, J., Wang, K., Chen, L., and Yang, Y. (2022). Front. Pharmacol. 13:912256. doi: 10.3389/fphar.2022.912256
Text Correction
In the original article, there was an error. Several result values were written incorrectly in the article’s abstract. The corrected abstract appears below:
In total, 16,710 and 11,937 PARP inhibitor AE reports were found in the FAERS and EV databases, of which 332 and 349 were associated with MDS and AML, respectively. The median latencies of MDS and AML associated with PARP inhibitors were 211 [interquartile range (IQR) 93.5–491.25] days and 355 (IQR 72.00–483.50) days, respectively. The average fatality rates of MDS and AML caused by the four PARP inhibitors were 39.23 and 45.39%, respectively, in the FAERS database, while those in the EV database were 32.32 and 34.94%, respectively. Based on the criteria used for the three algorithms, a significant disproportionate association was found between PARP inhibitors as a drug class and MDS/AML. Notably, the risk of MDS was much higher than that of AML. Olaparib appeared to have a stronger association with MDS and AML than did other PARP inhibitors.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: PARP inhibitors, myelodysplastic syndrome, acute myeloid leukemia, pharmacovigilance, real-world
Citation: Zhao Q, Ma P, Fu P, Wang J, Wang K, Chen L and Yang Y (2022) Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data. Front. Pharmacol. 13:990048. doi: 10.3389/fphar.2022.990048
Received: 09 July 2022; Accepted: 11 July 2022;
Published: 11 August 2022.
Approved by:
Frontiers in Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Zhao, Ma, Fu, Wang, Wang, Chen and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kejing Wang, d3ltd2tqMDAxQDE2My5jb20=; Lin Chen, Y3FmeWNsQDEyNi5jb20=; Yang Yang, Y3FmeXl5MjAyMEAxNjMuY29t